TOXIC HEPATITIS AND AGRANULOCYTOSIS DUE TO CINCHOPHEN
Authors: P STERNLIEB, S H EISMAN
Journal: Annals of Internal Medicine (1957)

Case Reports1 October 1957TOXIC HEPATITIS AND AGRANULOCYTOSIS DUE TO CINCHOPHENPETER STERNLIEB, B.S., SYLVAN H. EISMAN, M.D.PETER STERNLIEB, B.S.Search for more papers by this author, SYLVAN H. EISMAN, M.D.Search for more papers by this authorAuthor, Article, and Disclosure Informationhttps://doi.org/10.7326/0003-4819-47-4-826 SectionsAboutPDF ToolsAdd to favoritesDownload CitationsTrack CitationsPermissions ShareFacebookTwitterLinkedInRedditEmail ExcerptCinchophen (phenylcinchoninic acid) was first synthesized by Doebner and Giesecke in 1887 and was introduced into the therapeutic armamentarium by Weintraub in 1911 as a uricosuric agent in the treatment of gout, and has been prescribed for rheumatoid arthritis, rheumatic fever, headache, neuritis, etc. In the two or three decades after its introduction cinchophen was used extensively in both prescribed and patent medications, despite the fact that attention had been called as early as 1923 to its serious undesirable side-effects. In that year Worster-Drought21reported a case of toxic hepatitis due to cinchophen administration. Up to 1948 approximately 230 such...Bibliography1. CaldwellAdamsAndersonDick ALJWJFAA: Agranulocytosis treated with cortisone, Canad. M. A. J. 62: 506, 1950. MedlineGoogle Scholar2. Coventry WD: Granulocytopenia, Minnesota Med. 22: 177, 1939. Google Scholar3. DiengottUngar DH: Effect of cortisone on carbon tetrachloride cirrhosis in rats, Arch. Path. 58: 449, 1954. Google Scholar4. EssellierJeanneretTobler AFRLR: Die Eosinophilen Granulocyten als selbstandiges System bei den Agranulocytosen, Schweiz. med. Wchnschr. 84: 685, 1954. MedlineGoogle Scholar5. Fitz-HughComroe TBI: Agranulocytic angina, Am. J. M. Sc. 185: 552, 1933. CrossrefGoogle Scholar6. GoodmanGilman LSA: The pharmacological basis of therapeutics, 2nd Ed. 1955, The Macmillan Company, New York, p. 302. Google Scholar7. HanzlikScottWeidenthalFetterman PJRWCMJ: Cinchophen, neocinchophen, and Novaspirin in rheumatic fever, J. A. M. A. 76: 1728, 1921. CrossrefGoogle Scholar8. Hueper WD: Cinchophen, Medicine 27: 43, 1948. CrossrefMedlineGoogle Scholar9. Kracke RR: Experimental production of agranulocytosis, Am. J. Clin. Path. 2: 11, 1932. CrossrefGoogle Scholar10. LenzerLockieBecker ARLMCF: Acute yellow atrophy following cinchophen administration, New England J. Med. 236: 500, 1947. CrossrefMedlineGoogle Scholar11. Morgan AA: Agranulocytosis, Brit. M. J. 2: 28, 1954. CrossrefMedlineGoogle Scholar12. PattersonDingmanSchwachmanThorn PRJFHGW: Chloretic action of cortisone, New England J. Med. 251: 502, 1954. CrossrefMedlineGoogle Scholar13. Perez-TamayoMurphyIhnen RWRM: Effect of cortisone and partial starvation on liver regeneration, Arch. Path. 56: 629, 1953. Google Scholar14. Rawls WB: Agranulocytopenia in a patient receiving cinchophen and synthetic vitamin K, New York State J. Med. 44: 626, 1944. Google Scholar15. Saler LS: Rational application of biostatic drugs in agranulocytosis, South. M. J. 45: 1050, 1952. CrossrefMedlineGoogle Scholar16. ShapiroLehman SL: A case of agranulocytosis following ingestion of cinchophen, Am. J. M. Sc. 192: 705, 1936. CrossrefGoogle Scholar17. ShortBauer CLW: Cinchophen hypersensitiveness, Ann. Int. Med. 6: 1449, 1933. LinkGoogle Scholar18. Taulaniemi E: ACTH treatment in agranulocytosis, Ann. med. int. Fenniae 43: 2, 1954. Google Scholar19. Virkkunen M: ACTH and cortisone in treatment of agranulocytosis and thrombocytopenia, Arch. Int. Med. 90: 580, 1952. CrossrefGoogle Scholar20. WisemanDoan BKCA: Monocytes, monocytosis, and monocytic leukemia, Ann. Int. Med. 8: 383, 1934. LinkGoogle Scholar21. Worster-Drought C: Toxic hepatitis due to Atophan, Brit. M. J. 1: 148, 1923. Google Scholar22. Zubrod CG: Personal communication (July 21, 1955). Google Scholar This content is PDF only. To continue reading please click on the PDF icon. Author, Article, and Disclosure InformationAffiliations: *Received for publication April 27, 1956.From the Medical Clinic, Hospital of the University of Pennsylvania, and the Department of Medicine, University of Pennsylvania, Philadelphia.Requests for reprints should be addressed to Sylvan H. Eisman, M.D., Hospital of the University of Pennsylvania, Thirty-sixth and Spruce Streets, Philadelphia 4, Pennsylvania. PreviousarticleNextarticle Advertisement FiguresReferencesRelatedDetails Metrics Cited byAntiproliferative, DNA cleavage, and ADMET study of substituted 2-(1-benzofuran-2-yl) quinoline-4-carboxylic acid and its estersClinical Utilization of Alkaline Phosphatase MeasurementsEXPERIMENTAL TOXIC INJURY OF THE LIVERInterpretation of the Liver BiopsyCLINICAL AND LABORATORY MANIFESTATIONS OF HEPATOTOXICITYExperimental and Clinical Aspects of Drug ToxicityRHEUMATISM AND ARTHRITIS: REVIEW OF AMERICAN AND ENGLISH LITERATURE OF RECENT YEARS (THIRTEENTH RHEUMATISM REVIEW)*CHARLEY J. SMYTH, M.D., F.A.C.P., ROGER L. BLACK, M.D., FELIX E. DEMARTINI, M.D., IVAN F. DUFF, M.D., F.A.C.P., EPHRAIM P. ENGLEMAN, M.D., F.A.C.P., DONALD C. GRAHAM, M.D., F.R.C.P.(C), MAX M. MONTGOMERY, M.D., F.A.C.P., HOWARD F. POLLEY, M.D., F.A.C.P., EDWARD F. ROSENBERG, M.D., F.A.C.P., CARLOS F. SACASA, M.D., F.A.C.P., OTTO STEINBROCKER, M.D., HANS WAINE, M.D., GEORGE M. WILSON JR., M.D.DRUG-INDUCED HEPATIC INJURY*HANS POPPER, M.D., F.A.C.P., FENTON SCHAFFNER, M.D., F.A.C.P. 1 October 1957Volume 47, Issue 4Page: 826-834KeywordsGoutHeadachesHepatitisHepatitis AHospital medicineHospitalsHyperthermiaOral administrationRheumatic feverRheumatoid arthritis ePublished: 1 December 2008 Issue Published: 1 October 1957 PDF downloadLoading ...